SD Biosensor Participates in the International Federation of Clinical Chemistry 'IFCC 2023'

Global in vitro diagnostics specialist SD Biosensor (Co-CEOs Lee Hyo-geun and Heo Tae-young) announced its participation in the ‘IFCC WorldLab·EuromedLab 2023 (hereinafter IFCC 2023)’ held in Rome, Italy.

Marking its 25th edition this year, IFCC 2023 took place over five days from May 21 to 25 local time at the La Nuvola Convention Center in Rome, Italy. IFCC is the world’s most prestigious society in the field of clinical chemistry and laboratory medicine. This year, WorldLab and EuromedLab were held simultaneously for the first time in 12 years, attracting a large number of experts from Europe and around the world.

Europe accounts for 28% of the global in vitro diagnostics market and is a key market. Following its participation in ECCMID, Europe’s largest clinical microbiology conference held in Denmark last April, SD Biosensor strengthened its presence in the European market by actively promoting its products at IFCC 2023.

SD Biosensor highlighted its flagship product by exhibiting the rapid molecular diagnostic platform STANDARD M10 (hereinafter ‘M10’), which has consistently achieved strong results in the Italian tender market, at the main booth location. In addition, the company showcased eight CE-approved cartridges that attracted visitors’ attention: ▲Flu/RSV/SARS-CoV-2 (simultaneous diagnosis of influenza and COVID-19) ▲MDR-TB (drug-resistant tuberculosis test) ▲MTB/NTM (tuberculosis test) ▲HPV (human papillomavirus test) ▲Arbovirus Panel (arbovirus test) ▲C.difficile (colon test) ▲SARS-CoV-2 (COVID-19 test) ▲SARS-CoV-2 Turbo (COVID-19 LAMP test).

Furthermore, separate exhibition spaces were set up to promote the fluorescent immunoassay brand ‘STANDARD F’ and the chronic disease and blood glucose monitoring brand ‘Chronic Care.’ Notably, at IFCC 2023, SD Biosensor co-operated the booth with its Italian subsidiary Relab S.R.L., introducing ‘Chronic Care,’ which will be officially launched in the Italian market from the second half of the year, signaling business expansion.

Marco Molinari, CEO of Relab S.R.L., said, “Many visitors showed great interest in the SD Biosensor exhibition booth. Especially with WorldLab and EuromedLab held simultaneously at IFCC 2023, it was an important opportunity to showcase the vast potential of SD Biosensor’s portfolio in the European market and to discover new sales opportunities.”

This content was produced with the assistance of AI translation services.